Hong Kong will ‘play it safe' with growth figures due to US tariffs: Paul Chan
Advertisement
Financial Secretary
Paul Chan Mo-po said on Sunday that the widespread effects of the
US tariff war were a major concern across the board during his recent visits to international summits.
'There are major uncertainties over the economic outlook,' he told a radio programme. 'The US tariffs have a huge impact, so in the near future, to play it safe, we might not readily make major changes to our gross domestic product estimates.'
The United States and China started trade talks in the Swiss city of Geneva this weekend, with US President Donald Trump calling it '
a very good meeting ' after discussions broke off on Saturday evening.
Chan had forecast in his
budget in February that the economy could see full-year growth of 2 to 3 per cent.
Financial Secretary Paul Chan was in Italy last week for the Asian Development Bank's annual meeting. Photo: Handout
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
9 minutes ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
South China Morning Post
19 minutes ago
- South China Morning Post
Japan pitches Tokyo as new UN hub while US steps back from world stage
As the United States increasingly retreats from global leadership, Japan is positioning itself to fill the void with Tokyo Governor Yuriko Koike's proposal that the United Nations shift some of its operations to the Japanese capital. Advertisement Koike returned to Japan on Sunday following an official visit to the US, where she addressed the Johns Hopkins School of International Studies in Washington and highlighted Tokyo's emergence as a major player on the world stage. During her visit, she also met with policy experts at the Hudson Institute think tank, where Tokyo's drive to become a sustainable metropolis was high on the agenda. On Thursday, Koike held a 15-minute meeting with UN Secretary General Antonio Guterres at the organisation's headquarters in New York. There, she proposed that more of the UN's offices be relocated to cities elsewhere in the world, including Tokyo. 'Tokyo would like to provide various types of support [to the UN],' Koike told reporters after the meeting, highlighting the city's advantages over other locations, such as 'public safety, security and now, with the weak yen, there are other positive aspects to life'. Advertisement Guterres acknowledged that his office had 'received offers of cooperation from various countries and regions', but declined to elaborate on the Japanese proposal or whether it might be pursued further.
HKFP
25 minutes ago
- HKFP
CK Hutchison eyes inviting Chinese ‘major strategic investor' to Panama ports deal
Hong Kong conglomerate CK Hutchison said Monday it was eyeing inviting a Chinese 'major strategic investor' to join a US-led consortium negotiating the sale of its global ports business outside China, including operations at the Panama Canal. The firm said in March it was offloading the firms — including operations in the vital Central American waterway — to a group led by asset manager BlackRock for US$19 billion in cash. The sale was seen as a political victory for US President Donald Trump, who had vowed to 'take back' the Panama Canal from alleged Chinese control, prompting Beijing's ire. China's market regulator said in March it was reviewing the deal. '(CK Hutchison) remains in discussions with members of the consortium with a view to inviting (a) major strategic investor from (China) to join as a significant member of the consortium,' the group said in a stock exchange filing. The firm added that changes to the consortium's membership and deal structure will be needed for the deal 'to be capable of being approved by all relevant authorities'. CK Hutchison announced in March it was offloading its global ports business outside China — including operations in the vital Central American waterway — to a group led by asset manager BlackRock for $19 billion in cash. The sale was seen as a political victory for US President Donald Trump, who had vowed to 'take back' the Panama Canal from alleged Chinese control, drawing Beijing's ire. China's market regulator said in March it was reviewing the deal. CK Hutchison said Monday that the 'period for exclusive negotiations' mentioned in the March announcement had expired, but that discussions will continue. It did not name the major Chinese investor. China's biggest shipping company Cosco was set to join the consortium and was requesting veto rights or equivalent powers, Bloomberg News reported. Bloomberg Intelligence analyst Denise Wong told the outlet that 'ongoing negotiations and the reported inclusion of Cosco Shipping in the consortium have likely eased concerns over Chinese regulatory hurdles, strengthening investor confidence in the deal's viability'. CK Hutchison said it 'intends to allow such time as is required for such discussions to achieve' a workable arrangement. It said it had stated on several occasions that it 'will not proceed with any transaction that does not have the approval of all relevant authorities'. Its Hong Kong-listed shares climbed nearly one percent Monday, while Cosco rose 0.5 percent. The consortium's original structure was designed to pass control of CK Hutchison's two Panama ports to BlackRock's Global Infrastructure Partners unit, while the remaining ports will go to Italian billionaire Gianluigi Aponte's Terminal Investment Limited. AFP has contacted Cosco for comment. The Panama Ports Company, a CK Hutchison subsidiary, has managed the port of Cristobal on the canal's Atlantic side and Balboa on the Pacific side since 1997, via a concession from the Panama government.
